Anticoagulation for Aortic Bioprosthesis (ANTIPRO)

• Status: Completed
• Trial end date: 2019-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the clinical and hemodynamic outcome in patients after aortic valve replacement. Half of the patients will receive warfarin + aspirin and the other half will receive only aspirin. The investigators will focus mainly on early bioprosthesis degeneration.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Instituto Nacional de Cirugia Cardiaca, Uruguay
• Collaborator: Universidad de la Republica
• Treatments: Aspirin; Warfarin

Criteria

Inclusion Criteria:

• Patients with indication of aortic valve replacement with porcine bioprosthesis

Exclusion Criteria:

• Concomitant mitral valve replacement

• Previous atrial fibrillation

• Previous use oral anticoagulation

• Contraindication for the use of oral anticoagulation (high risk of bleeding, intolerance, allergy)

• Jehovah witness

• Platelet count below 90,000.

• Liver disease